How do I manage refractory invasive pulmonary aspergillosis
Clinical Microbiology and Infection · 2024-06 · 30 (6) · 755-761
DOI: 10.1016/j.cmi.2024.01.015 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Microbiology and Infection, 2024-06. Verfasst von Paschalis Vergidis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Section of Infectious Diseases, Mayo Clinic, Rochester, MN, USA. Electronic address: vergidis.paschalis@mayo.edu. Hauptthemen laut MEDLINE: Invasive Pulmonary Aspergillosis, Antifungal Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: F2G, AbbVie, University of Pittsburgh.
Abstract (Originalsprache)
BACKGROUND: Invasive aspergillosis is associated with significant morbidity and mortality in patients with haematologic malignancies and haematopoietic cell transplant recipients. The prognosis is worse among patients who have failed primary antifungal treatment. OBJECTIVES: We aim to provide guidance on the diagnosis and management of refractory invasive pulmonary aspergillosis. SOURCES: Using PubMed, we performed a review of original articles, meta-analyses, and systematic reviews. CONTENT: We discuss the diagnostic criteria for invasive pulmonary aspergillosis and the evidence on the treatment of primary infection. We outline our diagnostic approach to refractory disease. We propose a treatment algorithm for refractory disease and discuss the role of experimental antifungal agents. IMPLICATIONS: For patients with worsening disease while on antifungal therapy, a thorough diagnostic evaluation is required to confirm the diagnosis of aspergillosis and exclude another concomitant infection. Treatment should be individualized. Current options include switching to another triazole, transitioning to a lipid formulation of amphotericin B, or using combination antifungal therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Infectious Diseases, Mayo Clinic, Rochester, MN, USA. Electronic address: vergidis.paschalis@mayo.edu.
- Institute for Infectious Diseases, University of Bern, Bern, Switzerland.
- Division of Hematology, Mayo Clinic, Rochester, MN, USA.
- Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA.
Förderung
- F2G
- AbbVie
- University of Pittsburgh
- Astellas Pharma US
Zitieren
APA
Vergidis, P., Sendi, P., Alkhateeb, H. B., & Nguyen, M. H. (2024). How do I manage refractory invasive pulmonary aspergillosis. Clinical Microbiology and Infection, 30(6), 755-761. https://doi.org/10.1016/j.cmi.2024.01.015
Vancouver
Vergidis P, Sendi P, Alkhateeb HB, Nguyen MH. How do I manage refractory invasive pulmonary aspergillosis. Clinical Microbiology and Infection. 2024;30(6):755-761. doi:10.1016/j.cmi.2024.01.015
BibTeX
@article{Vergidis2024,
author = {Vergidis, Paschalis and Sendi, Parham and Alkhateeb, Hassan B and Nguyen, M Hong},
title = {How do I manage refractory invasive pulmonary aspergillosis},
journal = {Clinical Microbiology and Infection},
year = {2024},
volume = {30},
number = {6},
pages = {755--761},
doi = {10.1016/j.cmi.2024.01.015}
}
EUVIMED